Breaking News Instant updates and real-time market news.

ANAB

AnaptysBio

$126.45

6.59 (5.50%)

, SNY

Sanofi

$39.91

0.19 (0.48%)

20:02
02/19/18
02/19
20:02
02/19/18
20:02

On The Fly: Top five weekend stock stories

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. AnaptysBio (ANAB) presented final data from its Phase IIa trial of ANB020 in 12 mod-to-severe adult atopic dermatitis patients. Jefferies analyst Biren Amin raised his price target on the shares to $145 from $101, noting that sustained efficacy on a single dose of '020 was seen up to day 78 at EASI-50 in 75% of patients, comparable to Phase II data from Sanofi (SNY) and Regeneron (REGN) competitor Dupixent. ANB020 beats if you account for single dose versus Q2 weeks of Dupi, the analyst contended. 2. Snap (SNAP) CEO Evan Spiegel sold about 2.7M shares of stock last week, worth over $50M, which is his first personal stock sale since the company went public, according to Recode. The sale was a small amount of the executive's over holdings, a little more than 1%, the report added. 3. General Electric (GE) lost $6B in 2017 after a series of charges and impairments, cut its dividend by 50%, and its accounting is under investigation by the Securities and Exchange Commission, but lately it has been attracting fresh attention from value-oriented investors, Andrew Bary wrote in this week's edition of Barron's. Nonetheless, the stock is not a bargain and could drop another 10% or more, he contended. 4. Disney (DIS) and Marvel Studios' "Black Panther" won the President's Day box office with a record-breaking estimate of $201.8M for the three days and $235M for the four-day holiday frame. Featuring a virtually all-black cast, the movie secured the fifth-biggest domestic opening of all time, surpassing all expectations. The superhero film scored 97% from Rotten Tomatoes and got an A+ CinemaScore from movie audiences. 5. Alphabet (GOOG; GOOGL), Lam Research (LRCX), Citigroup (C), Cummins (CMI), JPMorgan (JPM), Johnson & Johnson (JNJ), Walmart (WMT), Pfizer (PFE), Cisco (CSCO), AbbVie (ABBV), PepsiCo (PEP), 3M (MMM), Bristol-Myers (BMY), United Technologies (UTX), Texas Instruments (TXN), Abbott Laboratories (ABT), and Hovnanian Enterprises (HOV) saw positive mentions in Barron's.

ANAB

AnaptysBio

$126.45

6.59 (5.50%)

SNY

Sanofi

$39.91

0.19 (0.48%)

REGN

Regeneron

$332.15

-1.03 (-0.31%)

SNAP

Snap

$20.42

0.67 (3.39%)

GE

General Electric

$15.05

0.2 (1.35%)

DIS

Disney

$106.53

1.35 (1.28%)

GOOG

Alphabet

$1,094.80

5.28 (0.48%)

GOOGL

Alphabet Class A

$1,095.50

4.14 (0.38%)

LRCX

Lam Research

$187.91

2.2 (1.18%)

C

Citi

$76.82

-0.26 (-0.34%)

CMI

Cummins

$165.60

0.58 (0.35%)

JPM

JPMorgan

$114.68

-0.83 (-0.72%)

JNJ

Johnson & Johnson

$133.15

1.92 (1.46%)

WMT

Walmart

$104.78

1.55 (1.50%)

PFE

Pfizer

$36.26

0.55 (1.54%)

CSCO

Cisco

$44.33

0.25 (0.57%)

ABBV

AbbVie

$118.60

3.7 (3.22%)

PEP

PepsiCo

$111.06

0.09 (0.08%)

MMM

3M

$236.67

1.8 (0.77%)

BMY

Bristol-Myers

$68.96

-0.02 (-0.03%)

UTX

United Technologies

$129.26

-0.74 (-0.57%)

TXN

Texas Instruments

$104.47

-0.1 (-0.10%)

ABT

Abbott

$60.17

0.67 (1.13%)

HOV

Hovnanian

$2.24

0.12 (5.66%)

  • 19

    Feb

  • 20

    Feb

  • 21

    Feb

  • 23

    Feb

  • 23

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 27

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 05

    Mar

  • 06

    Mar

  • 06

    Mar

  • 06

    Mar

  • 07

    Mar

  • 07

    Mar

  • 07

    Mar

  • 08

    Mar

  • 08

    Mar

  • 13

    Mar

  • 18

    Mar

  • 25

    Mar

  • 28

    Mar

  • 29

    Mar

  • 29

    Mar

  • 04

    Apr

  • 13

    Apr

  • 02

    May

  • 03

    May

  • 30

    May

  • 13

    Jul

  • 12

    Oct

ANAB AnaptysBio
$126.45

6.59 (5.50%)

02/15/18
RHCO
02/15/18
NO CHANGE
Target $162
RHCO
Buy
AnaptysBio price target raised to $162 from $115 at SunTrust
SunTrust analyst Yatin Suneja raised his price target on AnaptysBio to $162 and kept his Buy rating following his conversations with the company CEO and CFO. Suneja notes that the management commentary is consistent in expectation of a trend toward tolerance in the peanut trial and a "low double digit increase" in FEV1 in the asthma trial. The analyst states that his NPV analysis suggests that peanut indication alone could be worth $133/share, thus noting "highly favorable risk-reward into data readout".
01/19/18
BARD
01/19/18
NO CHANGE
Target $144
BARD
Outperform
AnaptysBio price target raised to $144 from $81 at Baird
Baird analyst Neena Bitritto-Garg raised her price target on AnaptysBio to $144 from $81 as the company plans to report top-line data from its ongoing Phase 2 study of its peanut allergy drug candidate. The analyst sees expectations building for the company as the drug represent a significant upside opportunity. Bitritto-Gard reiterated her Buy rating on AnaptysBio shares.
01/23/18
FBCO
01/23/18
NO CHANGE
Target $135
FBCO
Outperform
AnaptysBio price target raised to $135 from $85 at Credit Suisse
Credit Suisse analyst Alethia Young raised her price target for AnaptysBio to $135 saying she sees "room for upside" given the company's "many catalysts" in the next 12-18 months. The analyst lists the ANB-020 peanut allergy data in Q1, asthma data in Q2 and additional atopic dermatitis data potentially to be presented at a medical meeting in February as the key near-term catalysts. Young increased her probability of success estimate for ANB-019 on generalized pustular psoriasis from 0% to 25% ahead of getting first patient data potentially in late 2018 or early 2019 and raised her probability of success on ANB-020 in peanut allergy from 10% to 25% ahead of upcoming proof of concept data. She continues to like the pipeline story and keeps an Outperform rating on shares of AnaptysBio.
02/19/18
JEFF
02/19/18
NO CHANGE
Target $145
JEFF
Buy
AnaptysBio price target raised to $145 from $101 at Jefferies
Jefferies analyst Biren Amin raised his price target for AnaptysBio (ANAB) to $145 after the company presented final data from its Phase IIa trial of ANB020 in 12 mod-to-severe adult atopic dermatitis patients. The shares closed Friday up $6.59, of 5.5%, to $126.45. Sustained efficacy on a single dose of '020 was seen up to day 78 at EASI-50 in 75% of patients, comparable to Phase II data from Sanofi (SNY) and Regeneron (REGN) competitor Dupixent, Amin tells investors in a research note. ANB020 beats if you account for single dose versus Q2 weeks of Dupi, the analyst contends. He keeps a Buy rating on AnaptysBio.
SNY Sanofi
$39.91

0.19 (0.48%)

01/24/18
FBCO
01/24/18
NO CHANGE
Target $105
FBCO
Neutral
Bioverativ price target raised to $105 from $65 at Credit Suisse
Credit Suisse analyst Martin Auster raised his price target for Bioverativ (BIVV) to $105 from $65 ahead of likely closing of the Sanofi (SNY) deal. The analyst reiterates a Neutral rating on Bioverativ's shares.
01/24/18
ARGS
01/24/18
DOWNGRADE
ARGS
Hold
Bioverativ downgraded to Hold from Buy at Argus
Argus analyst Jasper Hellweg downgraded Bioverativ (BIVV) to Hold from Buy after the company announced a deal to be acquired by Sanofi (SNY) for $105 per share in cash. Hellweg says the strong run-up in the stock and the forthcoming acquisition have fully valued the stock at current levels.
02/08/18
BERN
02/08/18
NO CHANGE
Target $45
BERN
Market Perform
Sanofi price target lowered to $45 from $50 at Bernstein
Bernstein analyst Tim Anderson lowered his price target for Sanofi to $45 from $50 following a "weak" quarter. The analyst reiterates a Market Perform rating on the shares.
REGN Regeneron
$332.15

-1.03 (-0.31%)

02/12/18
LEER
02/12/18
NO CHANGE
Target $502
LEER
Outperform
Data from Regeneron Eylea competitors should lift some overhang, says Leerink
Leerink analyst Geoffrey Porges says that the "confusing and somewhat lackluster data" presented over the weekend for Eylea's theoretical competitors should lift some of the overhang that Regeneron's stock has suffered from over the last 6 months. Novartis' (NVS) brolucizumab pivotal trial is confusing, and the data incomplete, and the analyst has serious doubts about the drug's approvability. Secondly, the addition of Ang2 inhibition to VEGF inhibition, while theoretically intriguing, has so far been of modest benefit despite Roche's (RHHBY) posturing, he contends. Porges reiterates an Outperform rating and $502 price target on Regeneron's shares.
02/11/18
PIPR
02/11/18
NO CHANGE
Target $494
PIPR
Overweight
Piper Jaffray remains a buyer of Regeneron after Roche data
Piper Jaffray analyst Christopher Raymond remains a buyer of Regeneron (REGN) shares after Phase 2 data from Roche's (RHHBY) VEGF/Ang2 bispecific RG7716 in diabetic macular edema. While RG7716 demonstrated stag-sig BCVA gains compared to Lucentis at week 24 in DME patients previously untreated with anti-VEGF therapies, key questions on safety and efficacy remain unanswered, he contends. Given this, the analyst thinks Regeneron's Eylea remains well-positioned in the DME space. Raymond reiterates an Overweight rating and $494 price target on Regeneron's shares.
02/09/18
02/09/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Twitter (TWTR) upgraded to Sector Perform from Underperform at RBC Capital with analyst Mark Mahaney saying the fourth quarter revenue and EBITDA were materially better than expected, and while MAU's were below consensus, DAU's grew for the first time at a double-digit rate. 2. iRobot (IRBT) upgraded to Outperform from Market Perform at Raymond James with analyst Mark Strouse saying he sees a more balanced risk/reward following the recent pullback in the shares. 3. Regeneron (REGN) upgraded to Outperform from Neutral at Baird with analyst Brian Skorney noting its selloff since last year and believes its valuation has reached a point where the selloff is overdone. 4. Teva (TEVA) upgraded to Sector Perform from Underperform at RBC Capital with analyst Randall Stanicky saying the 11% sell-off in the stock price following the company's guidance update has removed the debate around 2018 EBITDA target and sees limited downside from the current levels. 5. United Technologies (UTX) upgraded to Buy from Hold at Argus with analyst John Eade saying the company remains a leader in a number of global industries and should continue to benefit from population growth and middle class expansion in developing markets. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SNAP Snap
$20.42

0.67 (3.39%)

02/07/18
MSCO
02/07/18
NO CHANGE
Target $11
MSCO
Underweight
Snap's 'next story' still uncertain, says Morgan Stanley
Morgan Stanley analyst Brian Nowak noted that Snap's Q4 results were better than expected, but he thinks the durability of the momentum into 2018 is less certain. The analyst, who still sees challenges and uncertainties as Snap works to turn its platform around, only increased his 2018 and 2019 revenue estimates by 3% each following the Q4 report. Nowak edged up his price target on Snap to $11 from $10 and keeps an Underweight rating on the stock, which has been upgraded by at least six other firms this morning.
02/07/18
02/07/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lennar (LEN) upgraded to Overweight from Equal Weight at Barclays with analyst Michael Dahl saying he now expects higher returns, margins and growth, and thinks "strong" free cash flow" creates balance sheet optionality. 2. Chevron (CVX) upgraded to Outperform from Market Perform at Wells Fargo with analyst Roger Read saying he believes the energy sector's potential combination of growth and returns is attractive and could drive better shareholder returns in 2018. 3. Wynn Resorts (WYNN) was upgraded to Overweight from Neutral at JPMorgan and to Buy from Neutral at Nomura Instinet. 4. Snap (SNAP) was upgraded to Buy from Neutral at BofA/Merrill, to Hold from Sell at SunTrust, to Neutral from Underweight at JPMorgan, to In Line from Underperform at Evercore ISI, and to Outperform from Sector Perform at RBC Capital. 5. Spirit Airlines (SAVE) was upgraded to Outperform from Neutral at Macquarie and to Outperform from In-Line at Imperial Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/07/18
SRCH
02/07/18
UPGRADE
SRCH
Hold
Snap upgraded to Hold from Sell at Summit Insights
Summit Insights analyst Jonathan Kees upgraded Snap to Hold with a $16 price target telling investors recent strategies are showing signs of traction. The analyst notes cumulative changes are still early and fraught with execution and market risks, but gives management credit for the changes to the core product and to the ad model.
02/07/18
02/07/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Wynn Resorts (WYNN) downgraded to Neutral from Buy at Roth Capital with analyst David Bain citing the news of Steve Wynn stepping down as Chairman and CEO. 2. Snap (SNAP) downgraded to Negative from Neutral at Susquehanna. 3. Chipotle (CMG) was downgraded to Sell from Hold at Stifel and to Neutral from Buy at Mizuho. 4. Cboe Global Markets (CBOE) was downgraded to Neutral from Overweight at JPMorgan and to Neutral from Buy at Goldman Sachs. 5. Macom (MTSI) was downgraded to Neutral from Overweight at JPMorgan and to Equal Weight from Overweight at Barclays. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
GE General Electric
$15.05

0.2 (1.35%)

02/15/18
LEHM
02/15/18
INITIATION
Target $16
LEHM
Equal Weight
General Electric initiated with an Equal Weight at Barclays
Barclays analyst Julian Mitchell started General Electric with an Equal Weight rating and $16 price target. The analyst initiated 24 Multi-Industry companies with a Neutral sector view.
02/12/18
JPMS
02/12/18
NO CHANGE
Target $14
JPMS
Underweight
JPMorgan cuts GE price target to $14, sees potential downside to $10-$11
JPMorgan analyst C. Stephen Tusa lowered his price target for shares of General Electric to $14 from $16 while maintaining an Underweight rating on the name. The stock closed Friday up 47c to $14.94. The company's fundamentals remain "challenged/mixed," and are showing "few signs of a snap back," Tusa tells investors in a research note. GE's portfolio is still low growth, with weak free cash flow and too much leverage, raising a question around whether an equity raise is possible, Tusa writes. The analyst does not think the company needs to raise capital as of yet, but adds "it would certainly help to de-risk from any capital markets volatility, and provide an accelerated pathway to greater optionality." Tusa argues that the value that is left over for equity holders is below where the stock currently trades. His sum-of-the-parts value for GE is $13, with downside to $10-$11 per share "depending on the outcome of certain liabilities that are tough to call but have historically been money bad."
02/13/18
BMOC
02/13/18
NO CHANGE
Target $35
BMOC
Market Perform
Genpact price target raised to $35 from $32 at BMO Capital
BMO Capital analyst Keith Bachman raised his price target on Genpact (G) to $35, saying the company's revenue growth trajectory is improving thanks to the "strong demand environment, solid execution, and lower revenue mix impact from General Electric (GE)". The analyst contends that revenue growth rates can accelerate further if Global Clients can grow 10% per year and GE stabilizes. Bachman keeps his Market Perform rating on Genpact, noting that the stock price gains are limited because operating and free cash flow margins will not improve "meaningfully".
02/08/18
DBAB
02/08/18
NO CHANGE
Target $13
DBAB
Sell
Deutsche Bank cuts General Electric price target of $13 from $15
Deutsche Bank analyst John Inch cut his price target for General Electric shares to $13 from $15 after introducing a 2020 earnings per share estimate of 90c, which represents a year-over-year decline of 16%. The stock closed yesterday down 2c to $15.25. The analyst's model assumes GE divests its IS, Rail, Lighting and Baker Hughes businesses by 2020. The 90c estimate could prove too high if the SEC investigation required GE to reduce contract asset earnings, Aviation/Healthcare were to incur operational hiccups and/or if GE were to make additional divestitures, Inch tells investors in a research note. His sum-of-the-parts analysis yields a $12 per share value for General Electric. The analyst keeps a Sell rating on the shares.
DIS Disney
$106.53

1.35 (1.28%)

02/07/18
HDLY
02/07/18
NO CHANGE
Target $134
HDLY
Long-Term Buy
Disney price target raised to $134 from $128 at Hilliard Lyons
Hilliard Lyons analyst Jeffrey Thomison raised his price target on Disney (DIS) shares to $134 after the company's "encouraging" Q1 results, stating that he believes each operating segment has growth potential over the next few years and he views the pending deal for 21st Century Fox (FOXA) assets as a long-term positive. He maintains a Long-Term Buy rating on Disney.
02/07/18
RILY
02/07/18
NO CHANGE
Target $125
RILY
Neutral
Disney price target raised to $125 from $122 at B. Riley FBR
B. Riley FBR analyst Barton Crockett raised his price target for Disney to $125 citing an improved mix shift to theme parks following last night's results. He believes this deserves a higher multiple but keeps a Neutral rating on Disney shares.
02/08/18
BMOC
02/08/18
NO CHANGE
Target $95
BMOC
Underperform
Disney price target raised to $95 from $90 at BMO Capital
BMO Capital analyst Daniel Salmon raised his price target on Disney to $95, noting a Q1 earnings beat, strong performance in Parks segment, and the upcoming launch of ESPN+. The analyst keeps his Underperform rating however, warning that shares could retest the bottom of recent range as the positive initial "virtual multichannel video programming distributor" impact fades.
02/07/18
MSCO
02/07/18
NO CHANGE
Target $130
MSCO
Overweight
Disney risks stabilizing while OTT opportunity grows, says Morgan Stanley
Morgan Stanley analyst Benjamin Swinburne noted that ESPN sub losses were stable to slightly better than the prior quarter for a second quarter in a row, while the emergence of Virtual Multichannel Video Programming Distributors and the benefit of renewals set the network up for improved results even before the benefit of the direct-to-consumer app. While the impact of lost third-party licensing as a result of a pivot to over-the-top won't be clear for a while, Swinburne thinks leaning towards OTT is likely the right strategic move, he added. He maintains an Overweight rating on Disney with a $130 price target.
GOOG Alphabet
$1,094.80

5.28 (0.48%)

02/02/18
FBCO
02/02/18
NO CHANGE
Target $1400
FBCO
Outperform
Alphabet price target raised to $1,400 from $1,350 at Credit Suisse
Credit Suisse analyst Stephen Ju attributes greater than expected marketing spending to promote growth in hardware, cloud, and YouTube as driving the shortfall in Alphabet's operating profit compared to estimates, though he said investors should be "happy to underwrite the incremental marketing and capex" spending in pursuit of the longer-term opportunity. As bright spots in the quarter, Ju points to the company's disclosure that Google's Cloud business is now at a $1B per quarter run rate and likely growing well in the triple-digit range and the fact that device shipments in the hardware business are also growing over 100%. Ju raised his price target to $1,400 and keeps an Outperform rating on Alphabet shares.
02/02/18
02/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) was downgraded to Market Perform from Outperform at Bernstein and to Sector Weight from Overweight at KeyBanc. 2. Alphabet (GOOG, GOOGL) downgraded to Hold from Buy at Stifel with analyst Scott Devitt citing fourth quarter results and saying he has some longer-term concerns around competition from Amazon (AMZN), Google Cloud Platform market share, regulatory risk and rising traffic acquisition cost. 3. Hershey (HSY) downgraded to Neutral from Outperform at Credit Suisse with analyst Robert Moskow saying the stock deserves a "more narrow" valuation premium to food peers than in the past due to the deceleration of its growth rate and the stagnation of its profit margin. 4. Impinj (PI) was downgraded to Neutral from Buy at Dougherty, to Hold from Buy at Needham and Canaccord, and to Sector Perform from Outperform at RBC Capital. 5. Tractor Supply (TSCO) downgraded to Underperform from Buy at BofA/Merrill with analyst Elizabeth Suzuki saying the fourth quarter results were strong, but the outlook for 2018 was disappointing as management outlined expectations for operating margin compression and a store growth trajectory. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/15/18
MSCO
02/15/18
NO CHANGE
Target $28
MSCO
Underweight
Twitter price target raised to $28 from $15 at Morgan Stanley
Morgan Stanley analyst Brian Nowak said he underestimated Twitter's (TWTR) turnaround efforts throughout 2017 and he has raised his price target on the stock to $28 from $15 given the company's better revenue outlook and high incremental margins. However, despite Twitter's better than expected results, he still sees the stock being a relative underperformer from current levels when compared to faster growing peers like Facebook (FB) and Alphabet (GOOGL), he tells investors. Nowak keeps an Underweight rating on Twitter.
02/06/18
CHLM
02/06/18
NO CHANGE
Target $80
CHLM
Buy
Craig-Hallum remains a buyer of Nutrisystem as Google trends continue to lag
Craig-Hallum analyst Alex Fuhrman says Nutrisystem (NTRI) Google (GOOG; GOOGL) trends continue to lag, setting up a buying opportunity despite mixed indicators. Mixed indicators suggest the Nutrisystem brand is not likely to accelerate revenue growth in 2018 from 2017's 23% levels, however the analyst believes there is still strong potential to exceed his estimate of about 11% growth for the brand in 2018. He reiterates a Buy rating and $80 price target on Nutrisystem's shares.
GOOGL Alphabet Class A
$1,095.50

4.14 (0.38%)

02/05/18
ARGS
02/05/18
NO CHANGE
Target $1300
ARGS
Buy
Alphabet price target raised to $1,300 from $1,220 at Argus
Argus analyst Joseph Bonner raised his price target on Alphabet to $1,300, citing strong growth in mobile search as well as "significant revenue growth" from the company's next-generation businesses - YouTube, Google Cloud, and Google Play. The analyst contends that Alphabet is navigating the desktop-to-mobile paradigm shift successfully while adding that the stock valuation is attractive against the backdrop of rapidly expanding business.
LRCX Lam Research
$187.91

2.2 (1.18%)

01/30/18
DADA
01/30/18
NO CHANGE
Target $100
DADA
Buy
Advanced Energy customers'' comments suggest strong Q4, sayst DA Davidson
DA Davidson analyst Thomas Diffely previews Advanced Energy's (AEIS) Q4 earnings expected out this week, saying that "bullish industry comments" from the company's largest customers - Applied Materials (AMAT) and Lam Research (LRCX) - suggest that the "record 2017" year had a strong finish and 2018 is shaping up even better. Diffely contends that the shipments guidance from Lam Research and the recent strong equipment orders from TSMC (TSM) all bode well for the core semiconductor business, keeping his Buy rating and $100 price target on Advanced Energy.
01/25/18
RBCM
01/25/18
NO CHANGE
Target $245
RBCM
Outperform
Lam Research price target raised to $245 from $225 at RBC Capital
RBC Capital analyst Amit Daryanani raised his price target on Lam Research to $245 and kept his Outperform rating after a Q2 earnings beat and better than expected Q3 outlook. Daryanani notes that the company's expectation of double digit WFE growth in 2018 implies equipment spending topping $50B "comfortably". The analyst contends that the company is "well positioned" from its status as the "arms dealer" in the memory race, sustaining double digit or higher revenue and EPS growth.
01/25/18
NEED
01/25/18
NO CHANGE
Target $270
NEED
Buy
Lam Research price target raised to $270 from $235 at Needham
Needham analyst Y. Edwin Mok raised his price target on Lam Research to $270 and kept his Buy rating after a "solid" Q2 earnings and a "very strong" Q3 guidance. Mok says the company's strong growth "validates" its outperformance in WFE, adding that the March analyst event will feature a positive update on longer term earnings model.
02/02/18
STFL
02/02/18
NO CHANGE
STFL
Apple won't be dominant catalyst for semi, display spending, says Stifel
Stifel analyst Patrick Ho believes Apple (AAPL) will remain a key catalyst, but not the dominant catalyst, for semiconductor and display spending, citing the emerging market opportunities in many different markets, such as data centers, artificial intelligence, autonomous driving, cryptocurrency, and VR/AR. Ho said he remains "steadfast" in the view that Applied Materials (AMAT) is the best positioned company to benefit from these emerging semi and display trends, given its positioning in terms of 3D NAND and strength in the foundry segment. He also sees Lam Research (LRCX) benefiting on the memory front and KLA-Tencor (KLAC) on the advanced foundry/logic front and views suppliers like MKS Instruments (MKSI) and Entegris (ENTG) as also poised to benefit.
C Citi
$76.82

-0.26 (-0.34%)

01/17/18
VERF
01/17/18
DOWNGRADE
VERF
Hold
Citi downgraded to Hold from Buy at Vertical Group
01/17/18
RBCM
01/17/18
NO CHANGE
Target $85
RBCM
Outperform
Citi price target raised to $85 from $79 at RBC Capital
RBC Capital analyst Gerard Cassidy raised his price target on Citi to $85 and kept his Outperform rating following Q4 earnings. Cassidy says that non-cash charges from tax reform masked the quarter's performance, with underlying trends for Citi remaining strong. The analyst adds that CitiGroup importantly reiterated the $60B capital return goal through CCAR despite the regulatory capital hit from the tax legislation.
02/02/18
MSCO
02/02/18
NO CHANGE
MSCO
BofA, JPMorgan, Citi best positioned for tougher CCAR test, says Morgan Stanley
Morgan Stanley analyst Betsy Graseck said she had expected an easier stress test from the Federal Reserve but that the 2018 CCAR test actually seems tougher than last year, given the more intense recessions and lower asset prices modeled in it. A tougher test makes her less optimistic on her strong payout growth expectations, said Graseck, who sees Bank of America (BAC), JPMorgan (JPM) and Citi (C) as best positioned to "weather the storm" and increase payouts given their resilient balance sheets and significant excess capital. She sees Goldman Sachs (GS), which recently cut buybacks, as at risk from a tougher test, which likely weighs on the bank's 2018 ask, Graseck added.
01/17/18
01/17/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Neutral from Buy at Longbow with analyst Shawn Harrison saying the current iPhone cycle is "good, not great." 2. Dish (DISH) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst Benjamin Swinburne saying he now sees fewer likely buyers of its assets than hoped. 3. Juniper (JNPR) downgraded to Underweight from Equal Weight at Barclays with analyst Mark Moskowitz citing a lack of service provider rebound in 2018 as well as a rising threat from Arista in routing. 4. Citi (C) was downgraded to Hold from Buy at Vertical Group and to Market Perform from Outperform at Keefe Bruyette. 5. Shell Midstream (SHLX) downgraded to Hold from Buy at Stifel with the firm citing valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
CMI Cummins
$165.60

0.58 (0.35%)

02/02/18
OPCO
02/02/18
NO CHANGE
Target $207
OPCO
Outperform
Cummins price target raised to $207 from $192 at Oppenheimer
Oppenheimer analyst Noah Kaye raised his price target for Cummins to $207 ahead of the company's Q4 results on Tuesday morning. The analyst says channel checks indicate prolonged growth for the North American heavy duty truck market into fiscal 2019. He also sees the company benefiting from a lower corporate tax rate. Kaye keeps an Outperform rating on Cummins.
01/18/18
JPMS
01/18/18
NO CHANGE
JPMS
Class 8 truck retail sales reportedly up 31% in December, says JPMorgan
JPMorgan analyst Ann Duignan noted that ACT Research released final truck data for December, showing that North American Class 8 retail sales were up 31% year-over-year to 27,776 units in the month. Truck demand has an impact on Navistar (NAV), Paccar (PCAR), Cummins (CMI), Allison Transmission (ALSN) and Eaton (ETN), noted Duignan.
02/05/18
DBAB
02/05/18
NO CHANGE
Target $169
DBAB
Sell
Cummins should be sold on post-earnings rally, says Deutsche Bank
Deutsche Bank analyst Nicole DeBlase recommends selling Cummins should the stock rally on Tuesday's earnings report. While the company could beat expectations, NAFTA Class 8 production is likely to decline in 2019-2020, making a 2018 a likely earnings peak, DeBlase tells investors in a pre-earnings research note. The analyst lowered her price target for Cummins to $169 from $177 and keeps a Sell rating on the name.
01/19/18
BOFA
01/19/18
UPGRADE
Target $215
BOFA
Buy
Cummins upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Ross Gilardi Cummins to Buy and raised its price target to $215 from $200 saying he sees further upside driven by the still early recovery in the broader US capital spending outlook. The analyst raised estimates above consensus citing stronger US truck data as used truck prices are accelerating and Class 8 inventories are low, and believes there is a softer landing occurring in the China truck market. Gilardi contends Cummins could make accretive acquisitions given it has no net debt and notes the GE Transportation business could be a good fit for the company.
JPM JPMorgan
$114.68

-0.83 (-0.72%)

02/12/18
KBWI
02/12/18
UPGRADE
KBWI
Outperform
JPMorgan upgraded to Outperform from Market Perform at Keefe Bruyette
02/13/18
02/13/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. JPMorgan (JPM) upgraded to Outperform from Market Perform at Keefe Bruyette with analyst Brian Kleinhanzl saying he views the recent pullback in the shares as a buying opportunity. 2. Total (TOT) upgraded to Overweight from Equal Weight at Morgan Stanley and to Strong Buy from Outperform at Raymond James. 3. Celgene (CELG) upgraded to Overweight from Equal Weight at Barclays with analyst Geoff Meacham saying the current valuation largely reflects the risk. 4. Quest Diagnostics (DGX) upgraded to Outperform from Neutral at Credit Suisse with analyst A.J. Rice saying he believes the company has "substantial runway on several fronts," including its Optum partnership related to revenue cycle management, which he believes could reduce bad debts and claims denials. 5. Boeing (BA) upgraded to Buy from Hold at Edward Jones. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/13/18
KBWI
02/13/18
UPGRADE
Target $127
KBWI
Outperform
JPMorgan upgraded to Outperform from Market Perform at Keefe Bruyette
Keefe Bruyette analyst Brian Kleinhanzl upgraded JPMorgan to Outperform with an unchanged price target of $127. The analyst views the recent pullback in the shares as a buying opportunity.
02/05/18
BWSF
02/05/18
NO CHANGE
Target $194
BWSF
Sell
LendingTree lost JPMorgan as mortgage lending customer, says BWS Financial
BWS Financial analyst Hamed Khorsand reports that LendingTree (TREE) has lost JPMorgan Chase (JPM) as a mortgage lending customer, calling it the company's second "high-profile" mortgage lender loss in about a quarter. The loss of JPMorgan matters both because of how many loans it originates but also due to the read-through that the loss has on the concept of LendingTree's calling center adding value for the lender, according to Khorsand, who keeps a Sell rating and $194 price target on LendingTree shares.
JNJ Johnson & Johnson
$133.15

1.92 (1.46%)

01/04/18
RBCM
01/04/18
NO CHANGE
Target $54
RBCM
Outperform
Pacira price target raised to $54 from $50 at RBC Capital
RBC Capital analyst Randall Stanicky raised his price target on Pacira (PCRX) to $54 and kept his Outperform rating. Stanicky says his focus is on the company's expected pre-announcement for Q4 this week and his upcoming discussion with CEO Dave Stack on Monday regarding changes from CMS around unbundling of payments that could represent a game changing opportunity for the company's EXPAREL. The analyst notes that traction is building around Pacira's relationship with Johnson & Johnson (JNJ) on the ortho selling side, which marks about half of its revenue.
01/02/18
01/02/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) downgraded to Neutral from Overweight at JPMorgan with analyst Michael Weinstein saying he sees greater upside potential in other large cap names with J&J shares trading at 17.9 times his 2018 earnings estimate. 2. PG&E (PCG) downgraded to Sell from Neutral at Guggenheim and to Neutral from Buy at Goldman Sachs. Goldman analyst Michael Lapides saying resolution of claims from the California wildfires, if inverse condemnation is applied, could take years and "cash flow/balance sheet impacts could prove significant still." 3. Allstate (ALL) downgraded to Underperform from Market Perform at Keefe Bruyette with analyst Meyer Shields saying the company's margin expansion story has played out. 4. Cabot Oil & Gas (COG) downgraded two notches to Underperform from Outperform at Raymond James with analyst John Freeman citing valuation after "considerable" 2017 share outperformance. 5. Windstream (WIN) downgraded to Underweight from Neutral at JPMorgan with analyst Philip Cusick saying he sees fundamental business challenges continuing in both the near and long term. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/06/18
WELS
02/06/18
NO CHANGE
Target $160
WELS
Outperform
Johnson & Johnson talc litigation concerns appear overblown, says Wells Fargo
Wells Fargo analyst Lawrence Biegelsen says Johnson & Johnson shares were down partly due to concerns about ongoing litigation over allegations that its talcum power products are unsafe for use because they contain asbestos which can cause mesothelioma. Based on prior high-profile product liability cases in the drug and device sectors, the analyst believes any potential settlement would be manageable for Johnson & Johnson. He reiterates an Outperform rating and $160 price target on the shares.
01/18/18
MSCO
01/18/18
NO CHANGE
Target $157
MSCO
Equal Weight
Zytiga ruling a headwind, but doesn't change J&J thesis, says Morgan Stanley
Morgan Stanley analyst David Lewis noted that Johnson & Johnson suffered an adverse Zytiga IPR ruling, which he calls an incremental headwind. However, he added that a possible earlier generic Zytiga entry is irrelevant to his net present value for J&J shares and doesn't change his view that its Pharma growth accelerates in 2018. Lewis keeps an Equal Weight rating and $157 price target on J&J shares.
WMT Walmart
$104.78

1.55 (1.50%)

01/25/18
MSCO
01/25/18
NO CHANGE
Target $74
MSCO
Equal Weight
Tractor Supply worries about Amazon risk overblown, for now, says Morgan Stanley
Morgan Stanley analyst Simeon Gutman said his survey of 800 consumers living within 20 miles of a Tractor Supply (TSCO) store suggests there is no cause for immediate concern about the e-commerce threat in pet food, but there are "warning signs that bear watching." Chewy.com, Walmart.com (WMT) and Amazon (AMZN) are gaining significant traction online in pet food and the evolution of shopping patterns could pose a long-term risk to Tractor Supply, though the e-commerce risk does not appear imminent, said Gutman, who keeps an Equal Weight rating on Tractor Supply shares.
02/08/18
SBSH
02/08/18
NO CHANGE
Target $117
SBSH
Buy
Citi views upcoming Q4 earnings report from Walmart as catalyst
Citi analyst Kate McShane thinks Walmart's Q4 earnings report on February 20 will be a catalyst for the shares. Given positive holiday commentary from several retailers, the potential upside risk to comps is high, McShane tells investors in a pre-earnings research note. Her same-store-sales assumption for Q4 is up 3.0%, which is higher than the Street's up 2.0%. Should same-store-sales come in better than 3%, the stock will likely see "notable upside," McShane contends. The analyst keeps a Buy rating on Walmart with a $117 price target.
01/26/18
LEHM
01/26/18
NO CHANGE
Target $120
LEHM
Overweight
Walmart price target raised to $120 from $110 at Barclays
Barclays analyst Karen Short raised her price target for Walmart to $120 despite lowering her earnings estimates for the retailer. Short dropped her fiscal 2019 earnings per share estimate to $5.20 from $5.40 to reflect the increase in U.S. starting wages, the closure of certain Sam's Club stores and "increased visibility" into the U.S. tax rate. The analyst notes, however, that she didn't raise her price target for Walmart shares when increasing estimates for the entire sector due to tax reform. Short keeps an Overweight rating on Walmart.
02/14/18
BARD
02/14/18
UPGRADE
Target $85
BARD
Outperform
Target upgraded to Outperform from Neutral at Baird
Baird analyst Peter Benedict upgraded Target (TGT) to Outperform and raised his price target for the shares to $85 from $75. The stock closed yesterday up 3% to $73.88. Better than expected comps should help narrow Target's "still-meaningful" valuation gap versus the overall market and competitor Walmart (WMT), Benedict tells investors in a research note. He sees more room for the shares to run following the 13% year-to-date rally. The analyst believes Target's accelerated remodels, additional exclusive brand launches, and emerging convenience-oriented fulfillment options will serve as catalysts in 2018, in addition to easy compares in Q1.
PFE Pfizer
$36.26

0.55 (1.54%)

01/29/18
RHCO
01/29/18
NO CHANGE
Target $40
RHCO
Hold
Pfizer price target raised to $40 from $33 at SunTrust
SunTrust analyst John Boris raised his price target on Pfizer to $40 and kept his Hold rating ahead of this week's earnings. The analyst attributes the price outlook revision to the positive impact of the tax changes, but notes that "transformative large-scale M&A" is needed to bring about return to "robust" long-term growth.
02/16/18
SBSH
02/16/18
NO CHANGE
Target $78
SBSH
Buy
Three developments make Pfizer buying Bristol-Myers more likely, says Citi
Citi analyst Andrew Baum raised his price target for Bristol-Myers Squibb (BMY) to $78 from $72 saying three developments over the last week have increased the probability of a Pfizer (PFE) takeover to near 65% from 50%. Bristol closed yesterday up $3.64, or 5.6%, to $68.98. First, Bristol's revenue potential in non-small cell lung cancer is partly de-risked through Checkmate-227 tumor mutation burden data, Baum tells investors in a research note. Second, the NKTR-214 development collaboration and equity stake in Nektar Therapeutics (NKTR) could materially increase Bristol's Opdivo market share, the analyst adds. And third, he believes Pfizer's immuno-oncology efforts "are looking increasingly suspect." Bristol-Myers is likely Pfizer's last chance to have a meaningful position in the $50B-plus per annum immuno-oncology market, Baum contends. He reiterates a Buy rating on Bristol shares.
02/07/18
HCWC
02/07/18
NO CHANGE
Target $31
HCWC
Buy
Achaogen price target raised to $31 from $25 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Achaogen (AKAO) to $31 after the FDA classified the outcome of its Q4 reinspection of Pfizer's (PFE) McPherson, Kansas facility as Voluntary Action Indicated. The news provides a clear regulatory path for approval of plazomicin out of the McPherson facility, Arce tells investors in a research note. He views the outcome as an "important risk-reducing development" that removes an overhang on Achaogen shares. The analyst keeps a Buy rating on the name.
12/05/17
SBSH
12/05/17
NO CHANGE
Target $72
SBSH
Buy
Senate tax bill raises odds of Pfizer buying Bristol-Myers, says Citi
The Senate tax bill, which lowers the cost of bringing cash back home from outside the U.S., increases the probability of the "often-discussed" potential acquisition of Bristol-Myers Squibb (BMY) by Pfizer, Citi analyst Andrew Baum tells investors in a research note. The analyst points out that Pfizer has repeatedly underscored the importance of tax reform both from a competitive angle as well as from a merger perspective. Further, the analyst says that while Roche's (RHHBY) IMpower 150 Tecentriq lung cancer data in Geneva will take center stage this week, Bristol-Myers should benefit from two recent positive developments. The FDA's and Centers for Medicare and Medicaid Services' recommendation of Tumor Mutational Burden testing for lung cancer and other tumors will likely materially accelerate adoption and create more favorable reimbursement, Baum writes in a research note partially titled "Stars Converging for BMY." The analyst keeps a Buy rating on Bristol shares with a $72 price target. The stock closed yesterday down 76c to $62.47.
CSCO Cisco
$44.33

0.25 (0.57%)

02/15/18
MKMP
02/15/18
NO CHANGE
Target $48
MKMP
Neutral
Cisco price target raised to $48 from $38 at MKM Partners
MKM Partners analyst Michael Genovese raised his price target on Cisco to $48 after its Q2 results, saying the company posted a clean beat with growth in all major reporting segments, including infrastructure. Genovese points to product order growth of 5%, up from 1% in the prior quarter, allowing for Q3 revenue growth outlook of 3%-5% that's above his view of 1.5%. The analyst keeps his Neutral rating on Cisco despite the good quarter, noting "weak secular Routing trends in the Service Provider market" and soft performance in "more sophisticated large Enterprise customer".
02/16/18
MKMP
02/16/18
NO CHANGE
Target $285
MKMP
Neutral
Arista Networks price target raised to $285 from $190 at MKM Partners
MKM Partners analyst Michael Genovese raised his price target on Arista Networks (ANET) to $285, saying that while Q4 earnings beat consensus, the stock price fell on less than expected Cloud Titan sales. The analyst says that the vertical did not perform up to bull case expectations, with about 20% of workaround certifications slipping from Q4 to Q1 because of Cisco (CSCO) patent lawsuits. Longer term, Genovese keeps his Neutral rating on Arista Networks, saying the company is "fantastic" but its valuation is appropriate.
02/16/18
DADA
02/16/18
NO CHANGE
Target $300
DADA
Buy
Arista Networks price target raised to $300 from $224 at DA Davidson
DA Davidson analyst Mark Kelleher raised his price target on Arista Networks (ANET) to $300 after Q4 results, saying the company offers "good traction" in cloud data centers and an "unabated march" on Cisco (CSCO) market share through a "storm of patent litigation". Kelleher believes that Arista Networks can have "years of strong growth" and market share gains, having launched its new router products. The analyst keeps his Buy rating.
02/15/18
COWN
02/15/18
NO CHANGE
Target $51
COWN
Outperform
Cisco price target raised to $51 from $42 at Cowen
Cowen analyst Paul Silverstein raised his price target on Cisco to $51 from $42 as the Q2 results reinforced his investment thesis. He said the return to growth has arrived and was broad-based. Silverstein, who also called the company's stock buyback and increased dividend impressive, reiterated his Outperform rating on Cisco shares.
ABBV AbbVie
$118.60

3.7 (3.22%)

02/15/18
PIPR
02/15/18
NO CHANGE
Target $138
PIPR
Overweight
AbbVie price target raised to $138 from $130 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond noted that after "an unexpected (and somewhat alarming) mid-day trading halt," AbbVie announced its board's approval of a new capital allocation plan, as the company had indicated was in the works. Following the buyback increase and dividend hike, Raymond said the dividend yield rises to an "impressive" 3.5% and he now models the company repurchasing over 105M shares between 2018 and 2020. Given the impact of the buybacks on his EPS estimates, Raymond raised his price target on AbbVie shares to $138 from $130 and he keeps an Overweight rating on the stock.
01/31/18
JEFF
01/31/18
NO CHANGE
JEFF
Jefferies sees neutral impact on Biotech from State of the Union
Jefferies analyst Michael Yee sees a net neutral impact on Biotech stocks from President Trump's State of the Union speech last night. During the speech, Trump made comments about making lower drug prices a "priority" for the year, Yee tells investors in a research not titled "Drug Pricing Comments Not New or Surprising - But a Reminder of Rhetoric." The President, however, also commented on broader access to novel clinical trial drugs, Yee points out. After a "strong biotech rally" in January, the analyst assumes the sector, "at some point," will have some relative near-term pullback either on uncertainty about Trump commentary or some consolidation. Some of the analyst's Buy-rated names include AbbVie (ABBV), Amgen (AMGN), Eli Lilly (LLY) and Gilead Sciences (GILD).
02/02/18
ARGS
02/02/18
NO CHANGE
Target $145
ARGS
Buy
AbbVie price target raised to $145 from $120 at Argus
Argus analyst David Toung raised his price target on AbbVie to $145 and kept his Buy rating after a "solid" Q4 earnings report that also included a substantial boost from lower tax rates. Toung says AbbVie is likely to submit more applications for new products and expanded indications of existing drugs this year as it develops new growth drivers such as Imbruvica and Mavyret to complement the current large contribution from Humira.
02/05/18
JEFF
02/05/18
NO CHANGE
Target $25
JEFF
Hold
Acorda remains takeover candidate after competitor data, says Jefferies
Jefferies analyst Michael Yee believes the positive Phase III topline results from Acorda Therapeutics (ACOR) competitor Sunovion for APL-130277 in Parkinson's patients came in as expected. While APL-130277 data compares favorably over Inbrija's 3.92 point difference at week 12, Yee cautions to compare directly head-to-head since patient baseline characteristics could be different. Acorda remains a "reasonably likely" acquisition candidate in 2018 given its $300M-$500M-plus Parkinson's asset Inbrija, Yee tells investors in a research note. The analyst does not think Biogen (BIIB) should buy the company, but sees other potential suitors in AbbVie (ABBV), Allergan (AGN), Mitsubishi, Roche (RHHBY) and Shire (SHPG). He believes a takeover price could be north of $2B. Yee keeps a Hold rating on Acorda with a $25 price target.
PEP PepsiCo
$111.06

0.09 (0.08%)

02/14/18
EVER
02/14/18
DOWNGRADE
EVER
In Line
PepsiCo downgraded to In Line from Outperform at Evercore ISI
02/14/18
EVER
02/14/18
DOWNGRADE
EVER
In Line
PepsiCo downgraded to In Line at Evercore ISI on NAB issues
As reported earlier, Evercore ISI analyst Robert Ottenstein downgraded PepsiCo to In Line from Outperform. The analyst says that while the company's dividend increase is "important and positive", he no longer expects the company to outperform in the beverage sector amid an "array of issues" at North America Beverage segment limiting upside performance. Ottenstein also points to rising commodity prices and expectations of the company to increase marketing expenses in NAB if results do not materialize. potentially putting downward pressure on the second half of 2018 earnings.
02/14/18
02/14/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. PepsiCo (PEP) downgraded to In Line from Outperform at Evercore ISI with analyst Robert Ottenstein saying that while the company's dividend increase is "important and positive," he no longer expects the company to outperform in the beverage sector amid an "array of issues" at North America Beverage segment limiting upside performance. 2. Spark Therapeutics (ONCE) downgraded to Neutral from Overweight at JPMorgan with analyst Cory Kasimov saying he remains optimistic about the long-term outlook for the company, but notes the shares are now within 10% of his price target following the recent rally. 3. Chimerix (CMRX) downgraded to Underweight from Neutral at JPMorgan with analyst Jessica Fye saying with base-case timing for the AdAPT data well over a year away, the shares will underperform over the near term. 4. Avis Budget (CAR) downgraded to Sell from Neutral at Goldman Sachs with analyst David Tamberrino saying he believes transitory benefits from Hurricane recovery demand are waning, and headwinds from reduced residual values, higher interest rates, continued competition, and increased SG&A expenses will pressure Avis' earnings outlook. 5. Lexicon (LXRX) downgraded to Underweight from Neutral at JPMorgan with analyst Jessica Fye saying the Xermelo launch remains slow, and consensus estimates of $55M and $99M for 2018 and 2019 are too high. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/14/18
RHCO
02/14/18
NO CHANGE
Target $115
RHCO
Hold
PepsiCo price target lowered to $115 from $125 at SunTrust
SunTrust analyst William Chappell lowered his price target on PepsiCo to $115 from $125, saying it is surprising that investors are giving the company a pass on its decision to reinvest a majority of its tax savings back into the business. The analyst adds that while PepsiCo's North America Beverage segment organic sales improved sequentially to -3% from -5%, they remain below the multi-year track record of low-single-digit growth. While the company has plans for product innovation and brand building, the analyst contends that the flat growth remains a concern. Chappell keeps his Hold rating on PepsiCo.
MMM 3M
$236.67

1.8 (0.77%)

02/13/18
DBAB
02/13/18
UPGRADE
Target $275
DBAB
Buy
3M upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst John Inch upgraded 3M to Buy and raised his price target for the shares to $275 from $240. The company remains in the early innings of realizing cost-saving benefits from its reorganization, Inch tells investors in a research note. He expects the company's Business Transformation synergies to "meaningfully accelerate" beyond 2018. Further, after years of U.S. pricing headwinds, 3M could be on the cusp of realizing improved pricing trends, the analyst adds.
02/15/18
LEHM
02/15/18
INITIATION
Target $235
LEHM
Underweight
3M initiated with an Underweight at Barclays
Barclays analyst Julian Mitchell started 3M with an Underweight rating and $235 price target. The analyst initiated 24 Multi-Industry companies with a Neutral sector view.
01/24/18
01/24/18
UPGRADE
Target $285

Buy
3M upgraded to Buy ahead of earnings at Hilliard Lyons
As previously reported, Hilliard Lyons analyst Spencer Joyce upgraded 3M to Buy from Neutral, saying he sees as a tactical opportunity ahead of its earnings report as he expects estimates to rise following the company's Q4 earnings release. He raised his 2018 and 2019 EPS estimates to $10.44 and $11.19, respectively, based on a lower effective tax rate and adjusting for current forex rates. Joyce has a $285 price target on 3M shares.
01/24/18
01/24/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. McKesson (MCK) upgraded to Buy from Hold at Jefferies analyst Brian Tanquilut saying the combination of stabilizing generic drug pricing, a discounted valuation relative to peers and higher earnings estimates due to tax reform will "boost investor interest this year and push the stock's multiple to more appropriate levels." 2. Cree (CREE) upgraded to Hold from Sell at Williams Capital. 3. 3M (MMM) upgraded to Buy from Neutral at Hilliard Lyons with analyst Spencer Joyce saying he sees as a tactical opportunity ahead of its earnings report as he expects estimates to rise following the company's fourth quarter earnings release. 4. Energen (EGN) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Evan Calio saying he expects oil markets to tighten and gas to remain weak in 2018. 5. Capital City Bank (CCBG) was upgraded to Outperform from Market Perform at Hovde Group and to Hold from Sell at Sandler O'Neill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
BMY Bristol-Myers
$68.96

-0.02 (-0.03%)

02/15/18
02/15/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst David Risinger saying he has become more optimistic on the immuno-oncology Opdivo + Yervoy combo in first-line lung cancer, which he notes is the largest cancer market. 2. Salesforce (CRM) upgraded to Buy from Hold at Jefferies with analyst John DiFucci saying recent field checks indicate continued strong enterprise traction as well improved commercial segment momentum, likely due to moderating Microsoft (MSFT) competition. 3. Credit Suisse (CS) upgraded to Buy from Hold at Societe Generale. 4. FMC Corporation (FMC) upgraded to Buy from Neutral at Seaport Global with analyst Michael Harrison saying he sees near-term catalysts from the Ag market recovery and secular growth in lithium, which the company plans to spinoff. 5. Baidu (BIDU) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst Grace Chen citing expectations for search sales reacceleration in 2018, the potential catalyst of the iQiyi IPO and the long-term potential contributions from AI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/15/18
SBSH
02/15/18
NO CHANGE
Target $62
SBSH
Neutral
Alkermes catalysts are the major focus this year, says Citi
Citi analyst Liav Abraham says that while Alkermes' (ALKS) fiscal 2018 revenue outlook came in below expectations, catalysts are the "major force this year." The analyst expects data from two of the company's pivotal programs and clarity around the regulatory pathway for ALKS 5461. Further, the strategic value of ALKS 4230 "can also not be discounted," following the collaboration between Bristol-Myers (BMY) and Nektar Therapeutics (NKTR), Abraham tells investors in a post-earnings research note. ALKS 4230, an IL-2 inhibitor, gives Alkermes optionality as it is not an "obvious" fit into the company's psychiatry-oriented portfolio, the analyst contends. She keeps a Neutral rating on Alkermes with a $62 price target.
02/15/18
02/15/18
UPGRADE
Target $78

Overweight
Bristol-Myers upgraded on immuno-oncology growth prospects at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger upgraded Bristol-Myers (BMY) to Overweight from Equal Weight as he has become more optimistic on the immuno-oncology Opdivo + Yervoy combo in first-line lung cancer, which he notes is the largest cancer market. After the analyst reviewed combo toxicity in select combo studies with similar dosing as Bristol's CM-227 and compared cross trial against Merck's (MRK) Keynote-021G trial that tested Keytruda + chemo, he concluded that discontinuation rates due to side effects appear roughly comparable and now thinks Opdivo + Yervoy toxicity in lung cancer is likely to be acceptable. Risinger raised his price target on Bristol-Myers shares to $78 from $63.
UTX United Technologies
$129.26

-0.74 (-0.57%)

02/09/18
ARGS
02/09/18
UPGRADE
Target $150
ARGS
Buy
United Technologies upgraded to Buy at Argus on infrastructure spending prospect
As reported earlier, Argus analyst John Eade upgraded United Technologies to Buy from Hold with a price target of $150. Eade says the company remains a leader in a number of global industries and should continue to benefit from population growth and middle class expansion in developing markets. The analyst adds that the stock has outperformed the market over the past quarter and should see more upside ahead given the optimism over reduced corporate tax rates and prospects for increased infrastructure spending. Eade says his valuation gives him a price target of $140 on comparative multiple analysis and $160 based on his dividend discount model.
02/15/18
LEHM
02/15/18
INITIATION
Target $157
LEHM
Overweight
United Technologies initiated with an Overweight at Barclays
Barclays analyst Julian Mitchell started United Technologies with an Overweight rating and $157 price target. The analyst initiated 24 Multi-Industry companies with a Neutral sector view.
02/09/18
ARGS
02/09/18
UPGRADE
ARGS
Buy
United Technologies upgraded to Buy from Hold at Argus
TXN Texas Instruments
$104.47

-0.1 (-0.10%)

01/25/18
ARGS
01/25/18
NO CHANGE
Target $122
ARGS
Buy
Texas Instruments price target raised to $122 from $106 at Argus
Argus analyst Jim Kelleher raised his price target on Texas Instruments to $122 and kept his Buy rating, citing a positive longer term outlook that balanced a more cautious view on Q1. The analyst notes that despite the expectations of a higher earnings beat, the company showed strong 2017 growth in industrial and automotive segments, leading to ongoing margin expansion. Kelleher believes that the growth in demand and sufficient capacity to meet that demand positions Texas Instruments for continued revenue and EPS growth.
01/24/18
MSCO
01/24/18
NO CHANGE
Target $101
MSCO
Equal Weight
Texas Instruments report likely somewhat disappointing, says Morgan Stanley
Morgan Stanley analyst Joseph Moore noted that Texas Instruments' Q4 results, outside of tax reform, were basically in-line with expectations, which he said is likely somewhat disappointing given strong conditions and the stock rally ahead of the report. The company's guidance implies Q1 results that are "very slightly less than seasonal," which seems prudent, he added. Moore raised his price target on Texas Instruments to $101 from $92 as he raised estimates to reflect lower taxes and keeps an Equal Weight rating on the stock.
01/24/18
RHCO
01/24/18
NO CHANGE
Target $117
RHCO
Hold
Texas Instruments price target raised to $117 from $96 at SunTrust
SunTrust analyst William Stein raised his price target on Texas Instruments to $117 and kept his Hold rating after the company's Q4 earnings. Stein attributes the price target revision to an earnings boost from tax reform, also raising his FY18 EPS forecast to $5.01 from $4.58. The analyst adds however that the latest results justify his warning about the fundamental risk to semis from "shortages in complementary passive & discrete components" that could limit semi industry sales growth later this year.
01/30/18
SBSH
01/30/18
NO CHANGE
Target $59
SBSH
Neutral
Maxim Integrated takeover by Renesas unlikely, says Citi
Citi analyst Christopher Danely does not believe Renesas can afford Maxim Integrated (MXIM), and therefore feels a deal between the two companies is unlikely. A potential Renesas/Maxim merger would likely not impact other analog names such as Texas Instrument (TXN) and Analog Devices (ADI) as "the analog business moves glacially and high-end analog companies have separate niches," Danely tells investors in a research note. The analyst keeps a Neutral rating on Maxim Integrated with a $59 price target.
ABT Abbott
$60.17

0.67 (1.13%)

01/25/18
LEER
01/25/18
NO CHANGE
Target $68
LEER
Market Perform
Abbott price target raised to $68 from $60 at Leerink
Leerink analyst Danielle Antalffya raised her price target for Abbott to $68 from $60 after the company delivered another "solid" quarter with improving fundamentals, and as she believes sales growth momentum is poised to continue as new products launch. The analyst reiterates a Market Perform rating on the shares.
01/30/18
PIPR
01/30/18
NO CHANGE
Target $60
PIPR
Overweight
Study shows superior outcomes for Dexcom over Abbott, says Piper Jaffray
Results of the I HART study that were published in the Diabetic Medicine journal showed superior outcomes for those on the Dexcom's (DXCM) G5 compared to Abbott's (ABT) Libre, Piper Jaffray analyst JP McKim tells investors in a research note. Specifically, G5 reduced time spent in hypoglycaemia both during the day and at night versus Libre that actually increased time, McKim adds. The analyst believes that while patients in the trial were ideal Dexcom candidates given their increased risk of hypoglycemia, the data can be used to differentiate the technology in the eyes of payers. He believes both G5 and Libre have a place in the system for different patient populations. The analyst keeps an Overweight rating on Dexcom with a $60 price target.
01/30/18
ARGS
01/30/18
NO CHANGE
Target $80
ARGS
Buy
Abbott price target raised to $80 from $66 at Argus
Argus analyst David Toung raised his price target on Abbott to $80 and kept his Buy rating after strong Q4 top-line growth. Toung says the company's future expansion will be driven by the acquisitions of St. Jude Medical and Alere, as well as by the recent launch of new products, which merit a premium valuation.
02/12/18
OPCO
02/12/18
NO CHANGE
Target $67
OPCO
Outperform
Dexcom price target lowered to $67 from $72 at Oppenheimer
Oppenheimer analyst Steven Lichtman lowered his price target for Dexcom (DXCM) to $67 from $72 on lowered estimates, while reiterating an Outperform rating on the stock. The analyst recently surveyed high-volume U.S. endocrinologists on the latest in continuous glucose monitoring now with Abbott's (ABT) Libre Flash on the market. According to respondents, there is some impact on Dexcom new prescriptions since Libre launch and some current Dexcom patients are interested in switching, but the impact looks within expectations, he contends. Overall, Lichtman believes the rollouts of Libre and Medtronic's (MDT) 670G remain overhangs on Dexcom near-term, but his survey suggests an environment no worse than guidance and conditions on the ground should change again in 2H18 with approval of Dexcom's next-generation G6.
HOV Hovnanian
$2.24

0.12 (5.66%)

12/29/17
WEDB
12/29/17
NO CHANGE
WEDB
Wedbush raises homebuilder price targets due to new tax bill
Wedbush analyst Jay McCanless increased his price targets on homebuilders by an average of 13.6% to reflect the potential impacts from the new tax bill, though he noted that his estimates and targets could need to be adjusted as companies begin reporting earnings giving specific tax guidance. He made the largest target increases to PulteGroup (PHM), Century Communities (CCS) and Taylor Morrison (TMHC), he noted. Other publicly traded companies in the space include Beazer Homes (BZH), CalAtlantic (CAA), D.R. Horton (DHI), Hovnanian (HOV), KB Home (KBH), Lennar (LEN), M.D.C. Holdings (MDC) and Toll Brothers (TOL).
12/22/17
12/22/17
DOWNGRADE

On The Fly: Top analyst downgrades
Catch up on today's top analyst downgrades with this list compiled by The Fly: 1. Dynagas LNG (DLNG) downgraded to Hold from Buy at Stifel with analyst Benjamin Nolan saying although the new three-year contract extension with Statoil (STO) improves cash flow visibility, the rates were below expectations and the cash flow gap has widened. 2. Hovnanian (HOV) downgraded to Sell from Neutral at MKM Partners wiht analyst Megan McGrath saying the large positive move up on the heels of its earnings report followed what she viewed as "only a mildly positive quarter." 3. Bojangles (BOJA) was downgraded to Hold from Buy at Jefferies while Wingstop (WING) and Shake Shack (SHAK) were downgraded to Underperform from Hold. 4. WWE (WWE) and Live Nation (LYV) were downgraded to Neutral from Buy at Citi. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/22/17
MKMP
12/22/17
DOWNGRADE
MKMP
Sell
Hovnanian downgraded to Sell from Neutral at MKM Partners
12/22/17
12/22/17
DOWNGRADE
Target $1.75

Sell
Hovnanian downgraded to Sell after post-earnings jump at MKM Partners
As previously reported, MKM Partners analyst Megan McGrath downgraded Hovnanian to Sell from Neutral, stating that the large positive move up on the heels of its earnings report followed what she viewed as "only a mildly positive quarter." Revenues are likely to continue to decline well into 2018 and cost headwinds are rising, not abating, McGrath tells investors. She has a $1.75 price target on the stock, which closed yesterday at $2.99.

TODAY'S FREE FLY STORIES

FCAU

Fiat Chrysler

$19.33

-0.195 (-1.00%)

13:14
07/21/18
07/21
13:14
07/21/18
13:14
Hot Stocks
Fiat names Jeep head as CEO as Marchionne's health worsens »

In a statement, Fiat…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RACE

Ferrari

$139.98

-2.65 (-1.86%)

, PM

Philip Morris

$84.31

3.41 (4.22%)

13:10
07/21/18
07/21
13:10
07/21/18
13:10
Hot Stocks
Ferrari to name former Philip Morris chairman as CEO »

The Board of Directors of…

RACE

Ferrari

$139.98

-2.65 (-1.86%)

PM

Philip Morris

$84.31

3.41 (4.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

AMZN

Amazon.com

$1,813.84

0.99 (0.05%)

, TM

Toyota

$131.87

0.11 (0.08%)

12:51
07/21/18
07/21
12:51
07/21/18
12:51
Periodicals
Amazon, others working to counter Trump's tariff plans, Reuters says »

Big companies in the…

AMZN

Amazon.com

$1,813.84

0.99 (0.05%)

TM

Toyota

$131.87

0.11 (0.08%)

AA

Alcoa

$40.32

-1.36 (-3.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 16

    Aug

FCAU

Fiat Chrysler

$19.33

-0.195 (-1.00%)

12:47
07/21/18
07/21
12:47
07/21/18
12:47
Periodicals
Fiat Chrysler's Sergio Marchionne to step down, NYTimes reports »

Fiat Chrysler's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$19.33

-0.195 (-1.00%)

12:43
07/21/18
07/21
12:43
07/21/18
12:43
Periodicals
Fiat Chrysler to name Jeep's Manley as CEO, Reuters reports »

Fiat Chrysler has named…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BABA

Alibaba

$187.21

-0.14 (-0.07%)

, TCEHY

Tencent

$0.00

(0.00%)

12:40
07/21/18
07/21
12:40
07/21/18
12:40
Periodicals
Alibaba, Tencent in talks to buy stake in WPP's Chinese unit, Reuters says »

Alibaba (BABA) and…

BABA

Alibaba

$187.21

-0.14 (-0.07%)

TCEHY

Tencent

$0.00

(0.00%)

WPP

WPP

$76.08

1.52 (2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

AMZN

Amazon.com

$1,813.84

0.99 (0.05%)

, NFLX

Netflix

$361.33

-2.81 (-0.77%)

11:24
07/21/18
07/21
11:24
07/21/18
11:24
Periodicals
Amazon, Netflix to face tighter capital markets, Barron's says »

Since the Great…

AMZN

Amazon.com

$1,813.84

0.99 (0.05%)

NFLX

Netflix

$361.33

-2.81 (-0.77%)

TSLA

Tesla

$313.49

-6.85 (-2.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 01

    Aug

  • 07

    Aug

  • 16

    Aug

AB

AllianceBernstein

$29.90

-0.05 (-0.17%)

, BLK

BlackRock

$503.01

-1.42 (-0.28%)

11:17
07/21/18
07/21
11:17
07/21/18
11:17
Periodicals
BlackRock, T. Rowe Price look like bargains, Barron's says »

With shares of many…

AB

AllianceBernstein

$29.90

-0.05 (-0.17%)

BLK

BlackRock

$503.01

-1.42 (-0.28%)

BEN

Franklin Resources

$31.99

-0.28 (-0.87%)

IVZ

Invesco

$25.46

-0.245 (-0.95%)

LM

Legg Mason

$33.37

-0.13 (-0.39%)

TROW

T. Rowe Price

$119.87

-0.85 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 26

    Jul

  • 27

    Jul

ALV

Autoliv

$104.08

-0.57 (-0.54%)

, VNE

Veoneer

$50.81

-1.81 (-3.44%)

11:12
07/21/18
07/21
11:12
07/21/18
11:12
Periodicals
Automotive spinoffs offer exposure to autonomous, electric future, Barron's says »

Last month, Autoliv (ALV)…

ALV

Autoliv

$104.08

-0.57 (-0.54%)

VNE

Veoneer

$50.81

-1.81 (-3.44%)

DLPH

Delphi Technologies

$44.78

-0.355 (-0.79%)

APTV

Aptiv

$92.95

-2.02 (-2.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 08

    Aug

DDAIF

Daimler AG

$0.00

(0.00%)

, FCAU

Fiat Chrysler

$19.33

-0.195 (-1.00%)

07:58
07/21/18
07/21
07:58
07/21/18
07:58
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$19.33

-0.195 (-1.00%)

F

Ford

$10.56

-0.115 (-1.08%)

GM

General Motors

$39.39

0.08 (0.20%)

HMC

Honda

$29.18

-0.19 (-0.65%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$131.87

0.11 (0.08%)

VLKAY

Volkswagen

$0.00

(0.00%)

GOOG

Alphabet

$1,184.77

-2.37 (-0.20%)

GOOGL

Alphabet Class A

$1,198.05

-1.21 (-0.10%)

PFE

Pfizer

$37.33

-0.03 (-0.08%)

NVS

Novartis

$82.28

1.47 (1.82%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$42.38

0.44 (1.05%)

BA

Boeing

$354.92

-0.57 (-0.16%)

MRK

Merck

$62.51

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 25

    Jul

  • 25

    Jul

  • 27

    Jul

  • 08

    Aug

  • 15

    Aug

  • 22

    Aug

  • 10

    Sep

  • 10

    Sep

  • 18

    Sep

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 28

    Oct

  • 28

    Jan

  • 16

    Feb

  • 22

    Mar

ACN

Accenture

$166.47

-0.47 (-0.28%)

, EADSY

Airbus

$0.00

(0.00%)

04:55
07/21/18
07/21
04:55
07/21/18
04:55
Conference/Events
Farnborough International to hold an airshow »

Farnborough International…

ACN

Accenture

$166.47

-0.47 (-0.28%)

EADSY

Airbus

$0.00

(0.00%)

ATI

Allegheny Technologies

$26.65

0.08 (0.30%)

BAESY

BAE Systems

$0.00

(0.00%)

BDRBF

Bombardier

$0.00

(0.00%)

CAE

CAE

$20.96

0.17 (0.82%)

CW

Curtiss-Wright

$125.79

-0.12 (-0.10%)

DASTY

Dassault Systemes

$0.00

(0.00%)

ESLT

Elbit Systems

$118.98

0.64 (0.54%)

LMT

Lockheed Martin

$322.76

3.09 (0.97%)

BA

Boeing

$354.92

-0.57 (-0.16%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 30

    Jul

  • 02

    Aug

  • 06

    Aug

  • 16

    Aug

FNWB

First Northwest Bancorp

$16.11

0.36 (2.29%)

17:48
07/20/18
07/20
17:48
07/20/18
17:48
Hot Stocks
First Northwest Bancorp names Terry Anderson chief credit officer »

First Northwest Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCX

Freeport McMoRan

$15.75

-0.05 (-0.32%)

17:42
07/20/18
07/20
17:42
07/20/18
17:42
Hot Stocks
Freeport McMoRan CAO Michael Arnold to retire »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$74.87

-0.24 (-0.32%)

, XLU

Utilities SPDR

$52.28

-0.39 (-0.74%)

17:39
07/20/18
07/20
17:39
07/20/18
17:39
General news
Week ending ETF Scorecard: Financials lead, Energy slumps »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$74.87

-0.24 (-0.32%)

XLU

Utilities SPDR

$52.28

-0.39 (-0.74%)

IYR

DJ US Real Estate Index Fund

$80.23

-0.68 (-0.84%)

XLP

Consumer Staples Sector SPDR

$52.84

0.3 (0.57%)

XLY

Consumer Discretionary Sector SPDR

$112.15

-0.47 (-0.42%)

XLB

S&P Select Materials SPDR

$58.31

-0.21 (-0.36%)

XLF

Financial Select Sector

$27.57

0.065 (0.24%)

XLV

Health Care Select Sector SPDR

$86.74

-0.17 (-0.20%)

XLK

Technology Select Sector SPDR

$72.55

0.01 (0.01%)

XLI

Industrial Select Sector SPDR

$74.44

-0.09 (-0.12%)

GLD

SPDR Gold Trust

$116.56

0.74 (0.64%)

SLV

iShares Silver Trust

$14.59

0.18 (1.25%)

USO

United States Oil Fund

$14.15

0.025 (0.18%)

UNG

United States Natural Gas Fund

$22.38

-0.06 (-0.27%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$85.62

0.03 (0.04%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$115.27

-0.335 (-0.29%)

TLT

iShares 20+ Year Treasury Bond Fund

$120.78

-1.46 (-1.19%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.21

-0.35 (-0.34%)

SHY

iShares 1-3 Year Treasury Bond

$83.26

-0.005 (-0.01%)

IWD

iShares Russell 1000 Value

$123.07

-0.2897 (-0.23%)

IWF

iShares Russell 1000 Growth

$149.41

-0.04 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XRX

Xerox

$25.10

-0.095 (-0.38%)

, FUJIY

Fujifilm

$0.00

(0.00%)

17:25
07/20/18
07/20
17:25
07/20/18
17:25
Hot Stocks
Xerox, Centerview settle matters related to proposed Fuji tie-up »

On July 20, 2018, Xerox…

XRX

Xerox

$25.10

-0.095 (-0.38%)

FUJIY

Fujifilm

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

STON

StoneMor Partners

$3.61

-0.015 (-0.41%)

17:15
07/20/18
07/20
17:15
07/20/18
17:15
Hot Stocks
Breaking Hot Stocks news story on StoneMor Partners »

Oaktree Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEF

Telefonica

$8.70

0.07 (0.81%)

17:11
07/20/18
07/20
17:11
07/20/18
17:11
Downgrade
Telefonica rating change at Goldman Sachs »

Telefonica downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

, USO

United States Oil Fund

$14.15

0.025 (0.18%)

17:04
07/20/18
07/20
17:04
07/20/18
17:04
General news
Weekly CFTC Commitment of Traders highlights »

S&P500 net long 5.5K…

SPY

SPDR S&P 500 ETF Trust

$279.71

-0.24 (-0.09%)

USO

United States Oil Fund

$14.15

0.025 (0.18%)

GLD

SPDR Gold Trust

$116.56

0.74 (0.64%)

FXE

Euro Currency Trust

$112.46

0.83 (0.74%)

FXC

CurrencyShares Canadian Dollar Trust

$75.17

0.81 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZWI

Citizens Community Bancorp

$14.15

(0.00%)

17:02
07/20/18
07/20
17:02
07/20/18
17:02
Syndicate
Breaking Syndicate news story on Citizens Community Bancorp »

Citizens Community…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PKD

Parker Drilling

$0.30

-0.0044 (-1.46%)

17:01
07/20/18
07/20
17:01
07/20/18
17:01
Hot Stocks
Breaking Hot Stocks news story on Parker Drilling »

Whitebox Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

RSLS

ReShape Lifesciences

$1.47

-0.02 (-1.34%)

17:00
07/20/18
07/20
17:00
07/20/18
17:00
Hot Stocks
Breaking Hot Stocks news story on ReShape Lifesciences  »

Intracoastal Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BOX

Box

$26.13

-0.26 (-0.99%)

16:57
07/20/18
07/20
16:57
07/20/18
16:57
Initiation
Box initiated at First Analysis »

Box initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALDX

Aldeyra

$7.95

-0.15 (-1.85%)

16:53
07/20/18
07/20
16:53
07/20/18
16:53
Syndicate
Breaking Syndicate news story on Aldeyra »

Aldeyra files $250M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLRE

Greenlight Capital Re

$14.00

-0.15 (-1.06%)

16:46
07/20/18
07/20
16:46
07/20/18
16:46
Hot Stocks
Greenlight Capital Re announces departure of COO »

Greenlight Capital Ry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RVI

Retail Value

$34.56

0.2 (0.58%)

16:38
07/20/18
07/20
16:38
07/20/18
16:38
Hot Stocks
Breaking Hot Stocks news story on Retail Value »

Luxor Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.